DWT
ALLO icon

Dorsey & Whitney Trust’s Allogene Therapeutics ALLO Stock Holding History

Dorsey & Whitney Trust’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,265
Closed -$38.9K – 608
2023
Q3 		$38.9K Buy
+12,265
New +$53.7K ﹤0.01% 581

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Dorsey & Whitney Trust's ALLO Position: Q4 2023 in Review

Dorsey & Whitney Trust sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 12,265 shares — an estimated $38.9K sold.

Dorsey & Whitney Trust first reported a position in ALLO in Q3 2023 and held it in 1 quarter. The position peaked at $38.9K in Q3 2023. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

  • Dorsey & Whitney Trust reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Dorsey & Whitney Trust sold 12,265 Allogene Therapeutics shares in Q4 2023, an estimated $38.9K.
  • Dorsey & Whitney Trust first reported a position in Allogene Therapeutics in Q3 2023 and held it in 1 quarter.
  • Dorsey & Whitney Trust's Allogene Therapeutics position peaked at $38.9K in Q3 2023.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Dorsey & Whitney Trust's 13F filing for Q4 2023, filed 12 Feb 2024.